

Healthcare Common Procedure Coding System Quarterly Update Effective July 1st, 2025

The Centers for Medicare and Medicaid Services (CMS) publish updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the "[HCPCS Quarterly Update](#)" page. Be sure to update systems accordingly.

Drugs

NEW Codes

C9174 Injection, datopotamab deruxtecan-dlnk, 1 mg

C9175 Injection, treosulfan, 50 mg

J1326 Zolbetuximab-clzb, 2 mg

J9174 Injection, docetaxel (beizray), 1 mg

J9275 Injection, cosibelimab-ipdl, 2 mg

J9276 Injection, zanidatamab-hrii, 2 mg

J9289 Injection, nivolumab, 2 mg and hyaluronidase-nvhy

J9341 Injection, thiotepa (tepylute), 1 mg

J9342 Injection, thiotepa, not otherwise specified, 1 mg

J9382 Injection, zenocutuzumab-zbco, 1 mg

Q2058 Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

REVISED Codes

Bolded words are revised additions. Strikethroughs indicate revised deletions.

J1954 Injection, leuprolide acetate for depot suspension (~~elpro~~) (**lutrate depot**), 7.5 mg

J9292 Injection, pemetrexed **dipotassium** (~~avyxa~~), not therapeutically equivalent to J9305, 10 mg

DISCONTINUED Codes

C9173 Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram

C9301 Obecabtagene autoleucel, up to 410 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

C9302 Injection, zanidatamab-hrii, 2 mg

C9303 Injection, zolbetuximab-clzb, 1 mg

J9340 Injection, thiotepa, 15 mg

Procedures/Services

Discontinued Codes

G9037 Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional for the care of the patient and may include subsequent follow up on the specialist's recommendations; 30 minutes

G9038 Co-management services with the following elements; new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for which specialist is taking a co-management role; condition expected to last at least 3 months; comprehensive care plan established, implemented, revised, or monitored in partnership with co-managing clinicians; ongoing communication and care coordination between co-managing clinicians furnishing care